Recent studies have shown that low expression of MMS22L is associated with poor survival and lymph node metastasis and enhances tumor cell migration in ESCC (Luo et al., 2021), suggesting the feasibility of MMS22L as a tumor suppressor gene. Here, MMS22L is linked to neoplasm.